BCM
IMVT icon

Boxer Capital Management’s Immunovant IMVT Stock Holding History

Boxer Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-825,000
Closed -$20.4M – 38
2024
Q4 		$20.4M Buy
+825,000
New +$23.4M 1.74% 17

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Boxer Capital Management's IMVT Position: Q1 2025 in Review

Boxer Capital Management sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 825,000 shares — an estimated $20.4M sold.

Boxer Capital Management first reported a position in IMVT in Q4 2024 and held it in 1 quarter. The position peaked at $20.4M in Q4 2024. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

  • Boxer Capital Management reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
  • Boxer Capital Management sold 825,000 Immunovant shares in Q1 2025, an estimated $20.4M.
  • Boxer Capital Management first reported a position in Immunovant in Q4 2024 and held it in 1 quarter.
  • Boxer Capital Management's Immunovant position peaked at $20.4M in Q4 2024.
  • 193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.